Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis
- 1 June 2003
- journal article
- clinical trial
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 48 (6) , 829-835
- https://doi.org/10.1067/mjd.2003.307
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgarisJournal of the American Academy of Dermatology, 2003
- Treatment of psoriasis. Part 2. Systemic therapiesJournal of the American Academy of Dermatology, 2001
- Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trialThe Lancet, 2001
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesionsJournal of the American Academy of Dermatology, 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Consensus Workshop on the Toxic Effects of Long-term PUVA TherapyArchives of Dermatology, 1998
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978